

## **Hong Kong | INVESTNOTES REPORTS REVIEW**

---

### Sectors:

Air & Automobiles (ZhangJing)  
Environmental protection & New energy(Wangyannan)  
Healthcare & Consumer (Eurus Zhou)

### **Automobile & Air (ZhangJing)**

This month I released 1 macro strategy report and 2 equity reports including China Southern Airline CSA (1055 HK) and Air China AC(753 HK), which got success by their unique Competitive edge.

In 2017, the world economy showed a steady recovery. We expect the U.S. economy to continue recovering steadily in 2018 and normalize its monetary policy. After the better-than-expected 2017, the European economy will continue its steady recovery and gradually withdraw from its QE. Japan will still maintain a loose monetary tone. In emerging markets, there will be differentiation and China's economy will continue to progress steadily.

On the premise of the improvement of the supply and demand pattern, we expressed cautious optimism for the promotion of the industry next year. In August, CSA raised H-shares and introduced U.S. airline strategy investors, which was expected to help to develop the company's Euro-American flight. At the same time, the company's project of raising RMB13.3 billion is moving forward, which will further increase assets when finished. The "accumulate" rating is given.

### **Environmental protection (Wang Yannan)**

This month, I have issued 4 research reports, namely LK(600388.SH), BGE(603588.SH),WEIMING(603568.SH),CEB(1257.HK). We tend to highly recommend BGE(603588.SH). Beijing GeoEnviron Engineering & Technology has strong overall strength in the soil remediation field, and at the same time, has accelerated its layouts in the dangerous wastes disposal and garbage burning fields, bringing sufficient momentum for continuous result growth. A few days ago, after the Company resumed trading by terminating its purchasing Shenzhen Shentou Environmental Technology Co, Ltd., the risk of falling short of expectations has been released to a large extent, and the controlling shareholders, supervisors and senior executives successively held more shares to show to the market their confidence in the long-term development of the company.

## Healthcare & Consumer (Eurus Zhou)

This month I released 3 equity reports, including Shanghai Pharma (2607.HK), Yunnan Baiyao (000538.CH) and Anta Sports (2020.HK). We tend to highly recommend Shanghai Pharma (2607.HK) and Yunnan Baiyao (000538.CH). As up to end of Sep, Shanghai Pharma reported revenue/net profit YoY growth of 9.41/9.42%, and we see improving operation with rising net operating cash inflow of RMB1.85bn (+0.54bn YoY). In Nov 2017, the company announced that its subsidiary would acquire 100% of Cardinal China (a foreign-capital pharmaceutical distributor in China). We estimate that inclusion of Cardinal business will enlarge the distribution revenue by c.15% in 18E. We see that distribution business turnover grew at 8.33% YoY in 9M17 and the company continues to expand the hospital supply chain innovation services. Manufacturing business grew at 18.7% YoY as up to end of Sep. We expect the manufacturing business to maintain quick growth as the company adheres to focus on key products and to strengthen the academic marketing-oriented strategy. 26 key products are expected to achieve more than 100mn sales in 17E. After the composite ownership reform, Yunnan Baiyao introduces more market-oriented decision making system and raises compensation to management. Manufacturing business reported FY11-16 CAGR 15.68% with average GPM 61.8%, while distribution segment recorded FY11-16 CAGR 14.8% with average GPM 6.81%. During the first half, manufacturing business grew at 9.5% YoY with GPM 66% (+4.79ppts) and distribution business achieved 17.5% YoY growth with increasing GPM 7.07% (+1.07ppts). We expect the topline to grow at 15.5%/13.4% in 17E/18E.

Fig 1. Performance of Recommended Stocks

Time	Ticker	Company	Analyst	Rating	Recommendation Date	Target Price	Expected Return	Month Closing Price	Month Return	Closing Price 2M ago	1M Price Chg
12/4/2017	600388.SH	LK	YN	BUY	15.75	20	26.98%	17.17	9.02%	15.75	9.02%
12/6/2017	1055 HK	CSA	ZJ	Accumulate	7.15	8.45	18.18%	7.85	9.79%	6.98	12.46%
12/11/2017	2607.HK	Shanghai Pharma	Eurus	BUY	19.42	25.2	29.80%	20.85	7.36%	19.78	5.41%
12/12/2017	603588.SH	BGE	YN	BUY	12.52	18	43.77%	12.74	1.76%	11.87	7.33%
12/14/2017	753 HK	AC	ZJ	Accumulate	8.06	8.67	7.57%	9.18	13.90%	8.38	9.55%
12/18/2017	000538.CH	Yunnan Baiyao	Eurus	Accumulate	99.34	117.7	18.50%	101.66	2.34%	103.4	-1.68%
12/20/2017	603568.SH	WEIMING	YN	BUY	20.8	25.5	22.60%	21.03	1.11%	20.47	2.74%
12/22/2017	2020.HK	Anta Sports	Eurus	Accumulate	31.75	36.6	15.30%	35.4	11.50%	36.45	-2.88%
12/28/2017	1257.HK	CEB	YN	BUY	6.95	8.84	27.19%	7.01	0.86%	6.67	5.10%

A stock is calculated by RMB yuan.

Source: Company, Phillip Securities Research

**PHILLIP RESEARCH STOCK SELECTION SYSTEMS**

Total Return	Recommendation	Rating	Remarks
>+20%	Buy	1	>20% upside from the current price
+5% to +20%	Accumulate	2	+5% to +20% upside from the current price
-5% to +5%	Neutral	3	Trade within $\pm$ 5% from the current price
-5% to -20%	Reduce	4	-5% to -20% downside from the current price
<-20%	Sell	5	>20% downside from the current price

We do not base our recommendations entirely on the above quantitative return bands. We consider qualitative factors like (but not limited to) a stock's risk reward profile, market sentiment, recent rate of share price appreciation, presence or absence of stock price catalysts, and speculative undertones surrounding the stock, before making our final recommendation

**GENERAL DISCLAIMER**

This publication is prepared by Phillip Securities (Hong Kong) Ltd ("Phillip Securities"). By receiving or reading this publication, you agree to be bound by the terms and limitations set out below.

This publication shall not be reproduced in whole or in part, distributed or published by you for any purpose. Phillip Securities shall not be liable for any direct or consequential loss arising from any use of material contained in this publication.

The information contained in this publication has been obtained from public sources which Phillip Securities has no reason to believe are unreliable and any analysis, forecasts, projections, expectations and opinions (collectively the "Research") contained in this publication are based on such information and are expressions of belief only. Phillip Securities has not verified this information and no representation or warranty, express or implied, is made that such information or Research is accurate, complete or verified or should be relied upon as such. Any such information or Research contained in this publication is subject to change, and Phillip Securities shall not have any responsibility to maintain the information or Research made available or to supply any corrections, updates or releases in connection therewith. In no event will Phillip Securities be liable for any special, indirect, incidental or consequential damages which may be incurred from the use of the information or Research made available, even if it has been advised of the possibility of such damages.

Any opinions, forecasts, assumptions, estimates, valuations and prices contained in this material are as of the date indicated and are subject to change at any time without prior notice.

This material is intended for general circulation only and does not take into account the specific investment objectives, financial situation or particular needs of any particular person. The products mentioned in this material may not be suitable for all investors and a person receiving or reading this material should seek advice from a financial adviser regarding the suitability of such products, taking into account the specific investment objectives, financial situation or particular needs of that person, before making a commitment to invest in any of such products.

This publication should not be relied upon as authoritative without further being subject to the recipient's own independent verification and exercise of judgment. The fact that this publication has been made available constitutes neither a recommendation to enter into a particular transaction nor a representation that any product described in this material is suitable or appropriate for the recipient. Recipients should be aware that many of the products which may be described in this publication involve significant risks and may not be suitable for all investors, and that any decision to enter into transactions involving such products should not be made unless all such risks are understood and an independent determination has been made that such transactions would be appropriate. Any discussion of the risks contained herein with respect to any product should not be considered to be a disclosure of all risks or a complete discussion of such risks.

Nothing in this report shall be construed to be an offer or solicitation for the purchase or sale of a security. Any decision to purchase securities mentioned in this research should take into account existing public information, including any registered prospectus in respect of such security.

**Disclosure of Interest**

Analyst Disclosure: Neither the analyst(s) preparing this report nor his associate has any financial interest in or serves as an officer of the listed corporation covered in this report.

Firm's Disclosure: Phillip Securities does not have any investment banking relationship with the listed corporation covered in this report nor any financial interest of 1% or more of the market capitalization in the listed corporation. In addition, no executive staff of Phillip Securities serves as an officer of the listed corporation.

**Availability**

The information, tools and material presented herein are not directed, intended for distribution to or use by, any person or entity in any jurisdiction or country where such distribution, publication, availability or use would be contrary to the applicable law or regulation or which would subject Phillip Securities to any registration or licensing or other requirement, or penalty for contravention of such requirements within such jurisdiction.

Information contained herein is based on sources that Phillip Securities (Hong Kong) Limited ("PSHK") believed to be accurate. PSHK does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. PSHK (or its affiliates or employees) may have positions in relevant investment products. For details of different product's risks, please visit the Risk Disclosures Statement on <http://www.phillip.com.hk>.

© 2017 Phillip Securities (Hong Kong) Limited

**Contact Information (Regional Member Companies)**

---

**SINGAPORE**

**Phillip Securities Pte Ltd**  
Raffles City Tower  
250, North Bridge Road #06-00  
Singapore 179101  
Tel : (65) 6533 6001  
Fax : (65) 6535 6631  
Website: [www.poems.com.sg](http://www.poems.com.sg)

**HONG KONG**

**Phillip Securities (HK) Ltd**  
Exchange Participant of the Stock Exchange of Hong Kong  
11/F United Centre 95 Queensway  
Hong Kong  
Tel (852) 22776600  
Fax (852) 28685307  
Websites: [www.phillip.com.hk](http://www.phillip.com.hk)

**INDONESIA**

**PT Phillip Securities Indonesia**  
ANZ Tower Level 23B,  
Jl Jend Sudirman Kav 33A  
Jakarta 10220 – Indonesia  
Tel (62-21) 57900800  
Fax (62-21) 57900809  
Website: [www.phillip.co.id](http://www.phillip.co.id)

**THAILAND**

**Phillip Securities (Thailand) Public Co. Ltd**  
15th Floor, Vorawat Building,  
849 Silom Road, Silom, Bangrak,  
Bangkok 10500 Thailand  
Tel (66-2) 6351700 / 22680999  
Fax (66-2) 22680921  
Website [www.phillip.co.th](http://www.phillip.co.th)

**UNITED KINGDOM**

**King & Shaxson Capital Limited**  
6th Floor, Candlewick House,  
120 Cannon Street,  
London, EC4N 6AS  
Tel (44-20) 7426 5950  
Fax (44-20) 7626 1757  
Website: [www.kingandshaxson.com](http://www.kingandshaxson.com)

**AUSTRALIA**

**PhillipCapital Australia**  
Level 12, 15 William Street,  
Melbourne, Victoria 3000, Australia  
Tel (613) 96188238  
Fax (613) 92002272  
Website: [www.phillipcapital.com.au](http://www.phillipcapital.com.au)

**MALAYSIA**

**Phillip Capital Management Sdn Bhd**  
B-3-6 Block B Level 3 Megan Avenue II,  
Number 12, Jalan Yap Kwan Seng, 50450  
Kuala Lumpur  
Tel (603) 21628841  
Fax (603) 21665099  
Website: [www.poems.com.my](http://www.poems.com.my)

**JAPAN**

**PhillipCapital Japan K.K.**  
Nagata-cho Bldg.,  
8F, 2-4-3 Nagata-cho,  
Chiyoda-ku, Tokyo 100-0014  
Tel (81-3) 35953631  
Fax (81-3) 35953630  
Website: [www.phillip.co.jp](http://www.phillip.co.jp)

**CHINA**

**Phillip Financial Advisory (Shanghai) Co. Ltd**  
No 436 Heng Feng Road,  
Green Tech Tower Unit 604,  
Postal code 200070  
Tel (86-21) 51699400  
Fax (86-21) 60911155  
Website: [www.phillip.com.cn](http://www.phillip.com.cn)

**FRANCE**

**King & Shaxson Capital Limited**  
3rd Floor, 35 Rue de la Bienfaisance 75008  
Paris France  
Tel (33-1) 45633100  
Fax (33-1) 45636017  
Website: [www.kingandshaxson.com](http://www.kingandshaxson.com)

**UNITED STATES**

**Phillip Futures Inc**  
141 W Jackson Blvd Ste 3050  
The Chicago Board of Trade Building  
Chicago, IL 60604 USA  
Tel +1.312.356.9000  
Fax +1.312.356.9005